Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
LXEO Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Lexeo Therapeutics, Inc. Common StockNASDAQ: LXEO
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 23.6% from a year ago
Other current liabilities stood at $1.3M at the end of Q1 FY2026, down 23.6% from a year earlier and down 68.6% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.
Context
- Other current liabilities amounted to 0.5% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -23.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.14M USD
- Year-over-year change
- -11.1%
- 4-year CAGR
- +44.1%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.14M | -11.1% |
| FY2024 | 2024-12-31 | 4.66M | +38.4% |
| FY2023 | 2023-12-31 | 3.36M | +56.4% |
| FY2022 | 2022-12-31 | 2.15M | +123.8% |
| FY2021 | 2021-12-31 | 961K | — |
Other Current Liabilities vs competitors
How LXEO compares with its peers on the latest reported figures
- LXEO's Mar 2026 other current liabilities of $1.3M is the 8th highest of the 11 companies compared; the peer median is $3.21M.
- Its year-over-year change of -23.6% is the 9th highest of 10, against a peer median of +44.2%.
- Other current liabilities amounts to 0.5% of total assets for LXEO, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $131.49M | — | +61.1% | 20.4% | |
| Mar 2026 | $81.65M | +30.8% | +36.9% | 18.8% | |
| Mar 2026 | $36.87M | +111.6% | — | 17.7% | |
| Mar 2026 | $6.73M | +184.9% | — | 2.1% | |
| Mar 2026 | $3.31M | +44.2% | +25.9% | 1.5% | |
| Mar 2026 | $3.11M | +1.1% | +160.5% | 1.2% | |
| Mar 2026 | $1.6M | +62.1% | -9.6% | 3.9% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $1.3M | -23.6% | +24.4% | 0.5% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $1.29M | +8.3% | +6.7% | 0.5% |
| Mar 2026 | $500K | +509.8% | -71.9% | 0.2% | |
| Mar 2026 | $0 | -100.0% | -14.3% | 0.0% | |
| Peer median (excluding LXEO) | $3.21M | +44.2% | +16.3% | 1.8% | |
Competitors are the stored peer set for LXEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 135.86M | 77.34M | 121.47M | 35.01M | 63M |
| Short-term Investments | 0 | 0 | 0 | 86.5M | 118.77M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 696K | 371K | 3K | 4.6M | 6.63M |
| Total Current Assets | 136.68M | 80.05M | 124.29M | 126.12M | 188.39M |
| Property, Plant & Equipment (Net) | 174K | 13.78M | 12.26M | 10.56M | 8.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 7.01M | 68.19M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2K | 7.49M | 3.25M | 3.25M | 3.25M |
| Total Non-current Assets | 176K | 21.26M | 15.51M | 20.82M | 80.3M |
| Total Assets | 136.86M | 97.08M | 139.81M | 146.94M | 268.69M |
| Account Payables | 3.06M | 2.68M | 3.79M | 6.42M | 4.86M |
| Short-term Debt | 0 | 0 | 0 | 2.67M | 0 |
| Tax Payables | 528K | 506K | 157K | 0 | 0 |
| Deferred Revenue | 46K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 961K | 2.15M | 3.36M | 4.66M | 4.14M |
| Total Current Liabilities | 7.45M | 14.35M | 17.24M | 22.85M | 16.81M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 185.01M | 185.03M | 0 | 0 | 0 |
| Total Non-current Liabilities | 185.01M | 195.68M | 9.03M | 7.25M | 5.21M |
| Total Liabilities | 192.46M | 210.03M | 26.27M | 30.1M | 22.02M |
| Common Stock | 1.68K | 0 | 3K | 3K | 7K |
| Retained Earnings | (56.17M) | (115.45M) | (181.84M) | (280.17M) | (380.13M) |
| Accumulated OCI | (185.01M) | (185.03M) | 0 | (103K) | 188K |
| Other Stockholders Equity | 863 | 185.03M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (55.6M) | (112.95M) | 113.54M | 116.84M | 246.67M |
| Total Debt | 0 | 13.48M | 11.64M | 9.92M | 7.89M |
| Net Debt | (135.86M) | (63.85M) | (109.83M) | (25.09M) | (55.11M) |
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
Intrinsic Alpha fair value
Locked
Current Price
$2.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.